Table 2.

Common side effects and their reported incidence from clinical trials.

Trial	Drug regimen	Bradycardia	Eye disorders including phosphenes
INITIATIVE	Ivabradine versus atenolol	2.2% (7.5 mg twice daily) and 5.4% (10 mg twice daily) versus 4.3% atenolol (p = NA)	5 withdrawals in the ivabradine group versus none in the atenolol group (p = NA)
ASSOCIATE	Ivabradine versus placebo	19 (4.2%) versus 2 (0.5%) (p = NA)	9 (2%) versus 4 (0.9%) (p = NA)
BEAUTIFUL	Ivabradine versus placebo	149 (6%) versus 21 (1%)* (p = NA)	21 (0.4%) versus 12 (0.2%)* (p = NA)
SHIFT	Ivabradine versus placebo	150 (5%) versus 32 (1%)$, 184 (6%) versus 48(1%)‡ (both p < 0.0001)	89 (3%) versus 17 (1%) (p < 0.0001)

^*Dropout rates – no reports of total incidence.

^$Symptomatic bradycardia.

^‡Asymptomatic bradycardia.

NA, not available/reported.